首页> 外文OA文献 >Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib

【2h】

Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib

机译：酪氨酸激酶受体AXL的表达与桑顿治疗的转移性肾细胞癌的更差

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Luís Eduardo Zucca; Mariana Andozia Morini Matushita; Renato José da Silva Oliveira; Cristovam Scapulatempo-Neto; Marcos Alves de Lima; Guilherme Gomes Ribeiro; Cristiano Ribeiro Viana; Flavio Mavignier Cárcano; Rui Manuel Reis;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib [J] . Zucca Luis Eduardo, Morini Matushita Mariana Andozia, da Silva Oliveira Renato Jose, Urologic oncology . 2018,第1期

机译：酪氨酸激酶受体AXL的表达与桑顿处理的转移性肾细胞癌的更差的结果有关
2. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience [J] . Matrana Marc R., Bathala Tharakeswara, Campbell Matthew T., BJU international . 2016,第2期

机译：一线帕唑帕尼治疗，血管内皮生长因子受体酪氨酸激酶抑制剂或雷帕霉素抑制剂的哺乳动物靶向治疗未选出的转移性透明细胞肾细胞癌患者的结果：单一机构经验
3. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma [J] . DaimonM., KatoT., KainoW., Japanese journal of clinical oncology. . 2012,第8期

机译：酪氨酸激酶抑制剂舒尼替尼，索拉非尼和阿昔替尼治疗的转移性肾细胞癌患者的甲状腺功能障碍
4. Proteomics Proteomics Reveals Overexpression of the Tyrosine Kinase AXL as a Novel Mechanism of Lapatinib Resistance in Breast Tumor Cells [C] . Roland S. Annan, Therese Collingwood, Francesca Zappacosta, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：蛋白质组学蛋白质组学显示酪氨酸激酶AXL的过表达作为乳腺肿瘤细胞中Lapatinib抗性的新机制
5. Receptor tyrosine kinase-like orphan receptor-1 (ROR1) expression in breast cancer stem cells can be targeted for anti-cancer-stem-cell therapy [D] . Liu, Grace. 2015

机译：乳腺癌干细胞中受体酪氨酸激酶样孤儿受体1（ROR1）的表达可用于抗癌干细胞治疗
6. Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors (VEGFR-TKI) or Mammalian Target of Rapamycin Inhibitors (mTORi): A Single Institution Experience [O] . Marc R. Matrana, Tharakeswara Bathala, Matthew T Campbell, -1

机译：一线帕唑帕尼治疗后再行血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFR-TKI）或雷帕霉素抑制剂（mTORi）靶向治疗的未选患者转移性透明细胞肾细胞癌患者的疗效：单一机构经验
7. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a sin [O] . Marc R. Matrana, Tharakeswara Bathala, Matthew T. Campbell, 2015

机译：未选择性透明细胞肾细胞癌的未选择患者的结果，用一线Pazopanib疗法治疗，然后进行血管内皮生长因子受体酪氨酸激酶抑制剂或哺乳动物靶蛋白抑制剂的靶标：罪

Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib

著录项

引文网络

相似文献

相关主题

期刊订阅